ALVENEX*OS SOSP 20BUST 450MG

ALVENEX*OS SOSP 20BUST 450MG

Therapeutic indications

Symptoms attributable to venous insufficiency; states of capillary fragility.

Dosage and method of use

One tablet or the content of one sachet of ALVENEX twice a day, at regular intervals, unless otherwise prescribed. Method of administration Tablets : swallow the tablet with the help of a modest amount of water. Powder for oral suspension : by shaking, disperse the contents of one sachet in a little water (about half a glass).

Contraindications

Hypersensitivity to the active substance or to any of the excipients. Pregnancy and breastfeeding.

Side effects

The use of ALVENEX at the recommended doses in therapy rarely gives rise to side effects. However, rare cases of gastralgia, nausea, diarrhea and dizziness are reported, always mild and such as not to require interruption of treatment.

System and organ classification	Common	Uncommon	Rare	Very rare	Not known (frequency not estimated from available data)
Nervous system disorders			Vertigo, Headache, Malaise
Gastrointestinal disorders	Diarrhea, Dyspepsia, Nausea, Vomiting	Colitis			Abdominal pain
Pathology of the skin and subcutaneous tissue			Rash, Itching, Urticaria		Edema of the face, lips, eyelids, Quincke's edema
Disorders of the blood and lymphatic system					Thrombocytopenia

Reporting of suspected adverse reactions Reporting suspected adverse reactions that occur after authorization of the medicinal product is important, as it allows continuous monitoring of the benefit / risk ratio of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via the national reporting system at https://www.aifa.gov.it/content/segnalazioni-reazioni-avverse.

Special warnings

There are no special precautions for the use of ALVENEX. For ALVENEX 450 mg powder for oral suspension: Patients with rare hereditary problems of fructose intolerance should not take this medicine. Keep out of the reach and sight of children.

Pregnancy and breastfeeding

The safety of the drug in pregnancy has not been determined; therefore it is advisable not to administer the medicine during pregnancy.

Expiration and retention

No special storage precautions.

Interactions with other drugs

No particular interactions have been detected so far. No interaction studies have been performed.

Overdose

No cases of overdose have been reported.

Active principles

One tablet contains: active ingredient : 450 mg diosmin One sachet contains: active ingredient : 450 mg diosmin For excipients, see 6.1

Excipients

ALVENEX 450 mg tablets Polyethylene glycol 4000, Magnesium stearate (E572), Talc, Silica, colloidal anhydrous. ALVENEX 450 mg powder for oral suspension Fructose, Polyethylene glycol 4000, Maize starch, Magnesium stearate (E572), Sweet orange essence.